PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
NMR Biomed. Author manuscript; available in PMC Oct 29, 2010.
Published in final edited form as:
Published online Feb 19, 2010. doi:  10.1002/nbm.1481
PMCID: PMC2891253
NIHMSID: NIHMS184029
T2 relaxation times of 13C metabolites in a rat hepatocellular carcinoma model measured in vivo using 13C-MRS of hyperpolarized [1-13C]pyruvate
Yi-Fen Yen,a* Patrick Le Roux,b Dirk Mayer,cd Randy King,c Daniel Spielman,c James Tropp,a Kim Butts Pauly,c Adolf Pfefferbaum,de Shreyas Vasanawala,c and Ralph Hurda
a Global Applied Science Laboratory, GE Healthcare, CA, USA
b Global Applied Science Laboratory, GE Healthcare, Europe
c Department of Radiology, Stanford University, Stanford, CA, USA
d SRI International, Neuroscience Program, Menlo Park, CA, USA
e Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA
* Correspondence to: Y.-F. Yen, GE Healthcare, 333 Ravenswood Avenue, Building 307, Menlo Park, CA 94025, USA. yi-fen.yen/at/ge.com
A single-voxel Carr-Purcell-Meibloom-Gill sequence was developed to measure localized T2 relaxation times of 13C-labeled metabolites in vivo for the first time. Following hyperpolarized [1-13C]pyruvate injections, pyruvate and its metabolic products, alanine and lactate, were observed in the liver of five rats with hepatocellular carcinoma and five healthy control rats. The T2 relaxation times of alanine and lactate were both significantly longer in HCC tumors than in normal livers (p < 0.002). The HCC tumors also showed significantly higher alanine signal relative to the total 13C signal than normal livers (p < 0.006). The intra- and inter-subject variations of the alanine T2 relaxation time were 11% and 13%, respectively. The intra- and inter-subject variations of the lactate T2 relaxation time were 6% and 7%, respectively. The intra-subject variability of alanine to total carbon ratio was 16% and the inter-subject variability 28%. The intra-subject variability of lactate to total carbon ratio was 14% and the inter-subject variability 20%. The study results show that the signal level and relaxivity of [1-13C]alanine may be promising biomarkers for HCC tumors. Its diagnostic values in HCC staging and treatment monitoring are yet to be explored.
Keywords: hyperpolarized 13C, T2 relaxation time, hepatocellular carcinoma, liver metabolism, in vivo metabolic MRS, Morris HCC model, alanine transaminase
T2 relaxation time has an impact on signal to noise ratios (SNRs) and image contrast, and is a critical consideration in the design of optimized pulse sequences. Recent progress in hyperpolarized 13C metabolic imaging (112) has demonstrated its potential as a technique to interrogate metabolic pathways, monitor metabolic changes in disease progression, and follow treatment. However, in vivo T2 relaxation times of metabolites detectable using hyperpolarized 13C-MRS methods remain largely uninvestigated. An attempt to measure in vivo T2 relaxation times of hyperpolarized [1-13C]pyruvate (noted herein as 13C-pyruvate) and its metabolic products was first reported by Yen et al. (13) with multiple T2 components found for each metabolite. However these T2 data were acquired from a whole slice, hence including signals from vasculature as well as the targeted organs, which may explain the multiple T2 components. Also noted from that study (13), the transgenic adenocarcinoma of mouse prostate (TRAMP) tumor seemed to have longer pyruvate, lactate, and alanine T2 relaxation times than rat kidney or dog prostate. However, due to limited number of animals (one for each animal/organ), results were inconclusive. In order to more accurately measure T2 values from both normal and diseased tissue, we developed a sequence to measure localized T2 from a single voxel and compared the localized T2 of hepatocellular carcinoma (HCC) tumor to normal liver.
The sequence consists of voxel-localization RF pulses followed by a Carr-Purcell-Meibloom-Gill (CPMG) echo train. LASER (14) sequence uses 3 pairs of adiabatic RF pulses (1519) for voxel selection. However, we found that adiabatic pulse pairs were too long for this application. In order to shorten the time to localize a voxel, we used a Shinnar–Le Roux (SLR) (20) 90° pulse for slice-selective excitation and two pairs of quadratic-phase SLR 180° pulses to refocus the slices (21,22) on orthogonal planes to localize a voxel. Details of the sequence are described in the Experimental Section. With this sequence, we measured both in vivo signal intensities and T2 relaxation times of 13C-labeled metabolites in rat livers after injection with hyperpolarized 13C-pyruvate solution, and investigated these measures as potential metabolic markers of HCC.
Hepatocellular carcinoma is a primary liver cancer, one of the most common tumors worldwide (23,24). Most HCC cases arise in the cirrhotic liver, which has a heterogeneous structure that makes detection challenging with conventional CT, MRI, or ultrasound. The cirrhotic liver has regenerative nodules, each of which may have a mass-like appearance, limiting the value of anatomic features to detect malignancy. As a result, currently, the most helpful feature for detecting malignancy is the Gd enhancement characteristics of lesions, though even this approach is hindered by poor specificity (25). We were interested in exploring potential metabolic biomarkers of HCC using hyperpolarized 13C MRS technique in an animal model. Rat HCC model developed by H. P. Morris (26) is a popular animal model. It is prepared by transplantation of different cell lines of hepatoma and has different gradations from types widely divergent from normal liver to types approaching normal liver. These models provide opportunities to study biological and biochemical parameters associated with different growth rates and energy metabolism regulations (2731). Here, we used a fast growing HCC model, Morris hepatoma 7777 (or McA-RH7777), to induce focal HCC lesions in the rat liver (32).
Elevated lactate in malignant tumors has been observed by proton spectroscopic imaging, as well as by hyperpolarized 13C techniques (2,6,810). Recent studies showed increasing [1-13C]lactate (noted herein as 13C-lactate) production, following the bolus injection of hyperpolarized 13C-pyruvate, correlated with disease progression in TRAMP model (2,6). Another study (8) demonstrated that TRAMP mice responding to hormone treatment exhibited reduction of 13C-lactate signal, whereas those not responding to treatment continued having high 13C-lactate signal. The increased 13C-lactate signal in these tumor models may be due to increased perfusion of pyruvate into these highly vascular tumors in combination with elevated lactate dehydrogenase (LDH) (11). High LDH reflects elevated anaerobic metabolism and increases pyruvate-to-lactate conversion rate, consistent with the ‘Warburg effect’ (33). Changes in lactate production can be quantified by estimating metabolic conversion rate constants using kinetic modeling techniques (11,34).
In contrast, studies (29,30) on metabolism regulations in Morris models showed that the LDH level in the fast growing HCC models, such as the Morris hepatoma 7777 model used here, is similar to the LDH level in normal liver. This is different from the LDH findings of other tumor models mentioned above. Therefore, we hypothesized that the 13C-lactate signal relative to the injected 13C-pyruvate, which was quantified as the total 13C signal (or total carbon) in this work, may not differentiate HCC tumor and normal liver. However, in some liver diseases, including hepatoma (35,36), the enzyme catalyzing pyruvate conversion to alanine, Alanine Transaminase (ALT), is elevated and we postulated a potential difference in 13C-alanine. In this study, hyperpolarized 13C-pyruvate was injected into both normal and HCC rats to measure both the signal levels and T2's of 13C-lactate and 13C-alanine.
Animal preparation
The experiment was performed using four male Wistar rats (283–459 g) with liver tumors prepared by using Morris hepatoma 7777 model (hereafter referred to as HCC rats), and five healthy male Wistar rats (361–578 g) as controls. The Morris 7777 model is a transplantable hepatoma rat model. The tumor cells were prepared in vitro at a growth rate of 80% confluency in 3 to 5 days. Approximately 1 million tumor cells were surgically implanted into the rat liver. The tumor growth was monitored weekly for MRI detectable tumors. Approximately 3 weeks after the implantation when at least one tumor had grown to 1 cm size, the HCC rat underwent the hyperpolarized 13C study. Immediately after the 13C study, the HCC rat was euthanized and necropsy was performed. Multiple tumor nodules and ascites were found in each of the HCC rats and the tumor sizes typically ranged from 2–3 mm to 1 cm. HCC rats were fasted 12–22 h prior to 13C scans.
Because the liver of Morris 7777 tumor model was highly heterogeneous and consisted multiple tumor lesions and nodules, we were not able to collect normal liver data from the HCC rats. Therefore, we acquired normal liver data from five healthy control rats. Two of the five controls underwent repeated hyperpolarized 13C scans for reproducibility test were fasted for 20 h and the remaining three were free feeding. Respiration, rectal temperature, heart rate, and oxygen saturation were monitored throughout each of the experiment, and animal was kept warm by using a water blanket regulated at 37°C. Animal preparation and physiological monitoring all followed a protocol approved by the Stanford University Administrative Panel on Laboratory Animal Care (APLAC).
Hyperpolarized 13C-pyruvate solution
A typical dose consisted of 40 mg [1-13C]pyruvic acid and 15 mM trityl radical mixture with 3 μl of a 1:25 aqueous dilution of ProHance® (Gadoteridol; Bracco Diagnostics, Inc., Princeton, NJ, USA). The mixture was polarized using Dynamic Nuclear Polarization technique and dissolved (37) in 4.6 g of TRIS/EDTA (trishydroxymethylaminomethane/ethylene diamine tetraacetic acid)-NaOH solution using a HyperSense™ polarizer (Oxford Instruments Molecular Biotools, Oxford, UK). The dissolved, hyperpolarized 13C-pyruvate solution was then transferred into a syringe, delivered to the animal inside the scanner, and administered manually into a tail-vein catheter. Each rat was injected with a 3 mL of 100 mM 13C-pyruvate bolus lasting 12–13 s. For each animal, injections were repeated two to three times at 2-h intervals. Since a desktop spectrometer was not available to measure liquid-state polarization for each injection, we relied on calibrations of liquid-state polarization by using the 3 T MRI scanner and the reproducibility of solid-state polarization on HyperSense. The 13C-pyruvate liquid-state polarization was approximately 15% to 20%, and the pH of the injected pyruvate solution was 7.4 ± 0.6.
MR Hardware and pulse sequence
A custom-built dual-tuned 1H/13C quadrature rat coil (38) was used for both RF excitation and signal reception. The 13C resonator had eight rungs with 8 cm inner diameter and approximately 9 cm length of homogeneous B1. All experiments were performed on a 3 T Signa™ MR Scanner (GE Healthcare, Waukesha, WI, USA) equipped with self-shielded gradients (40 mT/m, 150 mT/m/ms).
The pulse sequence consisted of voxel-localization pulses followed by a CPMG echo-train. The pulse sequence diagram is shown in Figure 1. Voxel selection was achieved by using an SLR (20) 90° RF pulse (1.75 kHz bandwidth) to selectively excite a slice, followed by two pairs of quadratic-phase SLR 180° pulses (5 kHz bandwidth) to selectively refocus slices in the other two orthogonal planes. All RF pulses have a pulse width of 5 ms. For each of the quadratic-phase pulses, a crusher gradient was applied before and one after the RF pulse on the axis where the slice-selective gradient was applied in order to dephase the spins in the RF transition band. For this study, the 90° selective-excitation was consistently applied on the axial plane (i.e. in the inferior to superior direction). The minimum voxel size was 1.1 cm (inferior to superior) × 1.2 cm (left to right) × 1.2 cm (anterior to posterior), equivalent to 1.6 cc. Depending on the metabolite chemical shift, the voxel location shifts slightly for different metabolites. The chemical shifts of 13C-lactate, 13C-alanine, and 13C-pyruvate are 185, 178, and 173 ppm, respectively. At 3T, the frequency difference is 225 Hz between 13C-lactate and 13C-alanine and 161 Hz between 13C-alanine and 13C-pyruvate. For data acquisition, we set the center frequency midway between 13C-lactate and 13C-pyruvate. Therefore, the 13C-alanine voxel was very close to the prescribed voxel location. The 13C-lactate voxel and the 13C-pyruvate voxel were shifted in the opposite directions from the prescribed location by 11% of the slice thickness in the inferior to superior direction and 4% in the other two directions.
Figure 1
Figure 1
Pulse diagram of the voxel-selective CPMG sequence used to measure T2 relaxation time of 13C metabolites. Voxel selection is achieved by using an SLR 90° slice-selective RF pulse of 1.75 kHz bandwidth, followed by two pairs of quadratic-phase (more ...)
A CPMG echo-train of 192 non-selective SLR 180° refocusing pulses (42 ms echo spacing) was employed to measure signal intensity and T2 decay from the localized voxel. Each refocusing pulse had a bandwidth of 1.74 kHz and pulse width of 5 ms. The first spin-echo signal was acquired 78 ms after the 90°-excitation RF pulse. This sequence was first validated on a 13C-enriched acetate spherical phantom (non-hyperpolarized) of 2 cm diameter, in comparison with T2 measurements by using a slice-selective CPMG sequence. Consistent T2 relaxation time of 4.7 ± 0.2 s was obtained from both methods.
MR Imaging protocol
Prior to each animal experiment, the 13C transmit gain was calibrated by using an 8 M 13C-urea syringe phantom placed near the center of the coil. Also placed inside the coil with the 13C-urea phantom was a 60 mL syringe filled with saline to properly load the coil. After the calibration, the animal was positioned inside the coil with its liver close to the middle of the coil to ensure homogeneous RF transmission. Proton T2-weighted (T2W) and spoiled gradient-echo images were collected for graphic voxel prescription. Then proton shimming was performed manually on a volume of approximately 2.5 cm × 2.5 cm × 2.5 cm covering the voxel of interest. For the hyperpolarized 13C acquisition on healthy rats, a voxel of 1.1 cm × 1.2 cm × 1.2 cm was prescribed in the liver avoiding major vessels such as the aorta and vena cava. For HCC rats, a voxel of the same size was placed on the 1 cm focal tumor. The 13C acquisition started 20 s after the start of the hyperpolarized 13C-pyruvate injection. A total of 192 echoes were acquired in 8 s with 604 points per echo and spectral bandwidth of 19.2 kHz. The acquisitions with hyperpolarized 13C-pyruvate injections were repeated three times on two of the control rats to assess intra-subject reproducibility.
Data analysis
The data were apodized in spectral domain with a 60 Hz Gaussian filter and zero-filled twice. Magnitude peak height was used to derive T2-decay curve of each metabolite. Because noise in the magnitude spectrum is not white, the true signal amplitude is biased when the signal level is low. A correction was performed following the algorithm in Ref. (39) in order to obtain accurate estimates of signal amplitudes in magnitude spectra. Ref. (39) suggested that for magnitude images of regions with no signal, the ratio of the average value to the standard deviation of the signal over this region should be given by 1.91. In our case, we tested the ratio of the average value to the standard deviation of the magnitude signal over a large spectral region away from metabolic peaks. From all spectra acquired in this study, we obtained 1.94 ± 0.01 which is close to 1.91, supporting the validity of applying this correction algorithm to our data. The correction factor as a function of magnitude SNR from Ref. (39) was used to determine the appropriate amount of bias to subtract from the magnitude signal in order to obtain the final T2-decay curve. When the magnitude SNR was greater than 30, the subtracted amount was less than 0.1% of the magnitude signal. Without this noise correction, overestimation of the T2 relaxation time is likely. Finally, mono-exponential curve fitting to the noise-corrected T2-decay data was performed using Nelder-Mead nonlinear least-square method in Matlab (The MathWorks, Inc., Natick, MA, USA) to estimate T2 relaxation time.
To compare signal intensities of metabolites between the HCC and control groups, the spectrum of the first spin-echo was fitted by four Gaussian peaks, one for each of the pyruvate, alanine, pyruvate-hydrate and lactate resonances. The alanine signal was estimated as the area of the fitted alanine peak, corrected for the respective T2 decay between the 90° excitation and the first spin-echo (78 ms), scaled for the amount of pyruvate solution injected per body weight (ml/kg), and corrected for the hyperpolarized 13C-pyruvate T1 relaxation between dissolution and injection. Lactate signal was estimated similarly. T1 of 58 s was used for the T1 relaxation correction. This value was obtained from a separate in vitro experiment, in which T1 was measured from a syringe of 3 mL hyperpolarized 13C-pyruvate solution using a pulse-and-acquire acquisition with constant 5° flip angles and TR of 3 s over 4 min. Total carbon signal was estimated as the sum of the four Gaussian peak areas, corrected for T2 decay, scaled by the injection dose (mL/kg) and corrected for 13C-pyruvate T1 relaxation before injection. For simplicity, an average value of the alanine T2 and lactate T2 was used for the T2 decay correction of the total carbon signal; that is 1.05 s for the HCC group and 0.45 s for the control group.
The prescription of a representative voxel in an HCC rat is illustrated in Figure 2a. This rat had two liver tumors, both exhibiting hyper-intense signal on the T2W proton image. Two 13C T2 data sets were acquired on this rat, one acquisition from each tumor. The corresponding spectra are shown in Figures 2b and 2c. Voxels acquired from control rats were prescribed consistently on the right lobe of the liver above the right kidney (Fig. 3a). A syringe containing an 8M 13C-urea solution was placed above the rat (Fig. 3b) and served as a reference for carbon transmit-gain calibration. A representative spectrum of normal liver (Fig. 3c) shows less 13C-alanine signal compared with the 13C-alanine signals in the tumor spectra (Figs 2b, 2c).
Figure 2
Figure 2
(a) Voxel prescription based on a T2W proton coronal image of a rat with two HCC tumors (white arrows); (b) and (c) representative 13C spectra of the tumors. Here P, A, P-H, and L indicate pyruvate, alanine, pyruvate-hydrate, and lactate peaks, respectively. (more ...)
Figure 3
Figure 3
(a) Voxel prescription on T2W proton coronal image of a healthy control rat; (b) proton sagittal image shows the voxel location and the 13C-urea reference syringe; (c) representative 13C spectrum of the normal liver. Here P, A, P-H, and L indicate pyruvate, (more ...)
We checked the effect of fasting on the control data. A liver metabolism study published previously by using hyperpolarized 13C-pyruvate MRSI showed significant increase of lactate to alanine ratio in fasted rats (40). The average alanine signal of (two) fasted rats in this study was (6±2) ×1012 and the average alanine of (three) free-fed rats (8 ± 1) × 1012. The average lactate signal was (1.01 ± 0.04) × 1013 for fasted rats and (8 ± 3) × 1012 for free-fed rats. The sample sizes in this study were too small to draw any significant conclusion comparing fasted to free-fed rats. However, our finding shows perhaps a trend of smaller alanine and larger lactate signal on fasted rats than free-fed rats, consistent to the published results (40). Since there is no significance separating the fasted and free-fed controls, we will report the results combining all five controls in this paper.
Intra-subject variation was estimated from repeated measurements performed on two of the control rats (both fasted). Inter-subject variability was assessed from independent measurements of the five different rats in the control group and only the first measurement of the repeated data sets was used. The intra- and inter-subject variations of the alanine T2 relaxation time were 11% and 13%, respectively. The intra- and inter-subject variations of the lactate T2 relaxation time were 6% and 7%, respectively. The intra-subject variability of alanine to total carbon ratio was 16% and the inter-subject variability 28%. The intra-subject variability of lactate to total carbon ratio was 14% and the inter-subject variability 20%.
The 13C metabolites in HCC tumors had longer T2 relaxation times than those in the normal livers, as demonstrated by the mean and ± standard-deviation (SD) of the T2 curves of each group in Figure 4 for (a) 13C-alanine, (b) 13C-lactate, and (c) 13C-pyruvate. For the two control rats on which repeated scans were performed, only the first data set was included in the analysis of the control group. The 13C-alanine T2 of HCC tumor (1.2 ± 0.1 s) was longer than that of normal liver (0.38 ± 0.05 s). Two-sample one-tail t-test comparing 13C-alanine T2 values between the HCC and control groups yielded p < 3 × 10−5. The 13C-lactate T2 was 0.9 ± 0.2 s in the HCC tumor and 0.52 ± 0.03 s in the normal liver. The t-test of the 13C-lactate T2 values between the two groups yielded p < 2 × 10−3. The T2 differences between the two groups were significant.
Figure 4
Figure 4
Mean (red solid lines) and ± one standard-deviation (red dashed lines) T2 decay curves acquired from 5 HCC tumors compared to mean (blue circles) and ± one standard-deviation (blue dotted lines) T2 decay curves from livers of 5 healthy (more ...)
The 13C-pyruvate signal decay curves were very noisy (Fig. 4c) and the noise frequency matched with the frequency of cardiac cycles. Following high dose injection of hyperpolarized 13C-pyruvate, substantial amount of 13C-pyruvate circulated in blood and experienced B1 inhomogeneity during the (non-selective) refocusing pulse train. The T2 signals were poorly refocused and the T2 curves cannot be described well by mono-exponential curve fitting. Inter-subject deviations were large. There seems to be no difference between control and HCC groups.
Figure 5 shows a scatter plot of total carbon signal vs individual metabolite signal. Corrections for T2 decay, injection dose and T1 relaxation before injection were applied. Four out of five tumors had higher total carbon signal than normal livers. On average, the total carbon signal found in a HCC rat tumor was 1.7 ± 0.5 times the total carbon signal observed in normal liver. There was no evidence for an effect of tumor size on the levels of lactate and alanine. All tumors had higher alanine signals than control livers (p < 3 × 10−3, tumor/control = 2.6 ± 0.9,). All but one tumor had higher lactate signal than normal livers (p < 7 × 10−3, tumor/control = 1.9 ± 0.7). However, because the total carbon in the HCC tumors was also higher than that in normal livers, it is possible that the individual metabolite signals may be high in tumors even though the production relative to the injected 13C-pyruvate (as quantified by the total carbon signal) may not be significantly different from normal livers. This is indeed the case observed for labeled lactate (Fig. 6a). The lactate signal relative to the total carbon in HCC tumors was 1.1 ± 0.3 times of that in normal livers, not a significant difference (p < 3 × 10−1). On the other hand, the alanine to total carbon ratio in HCC tumors was significantly higher (Fig. 6b), about 1.5 ± 0.5 times of that in normal livers (p < 6 × 10−3). The pyruvate to total carbon ratio is relatively low in HCC tumors comparing to normal livers most likely because relatively more labeled pyruvate was converted to alanine in tumors.
Figure 5
Figure 5
Scatter plot of total carbon signal vs. individual metabolite signal of 13C-alanine (red stars: HCC tumor, blue circles: normal liver), 13C-lactate (pink crosses: HCC tumor, green triangles: normal liver) and 13C-pyruvate (black pluses: HCC tumor, cyan (more ...)
Figure 6
Figure 6
(a) alanine to total carbon ratio of HCC tumors (red stars) and normal livers (blue circles); (b) lactate to total carbon ratio of HCC tumors (pink crosses) and normal livers (green triangles); (c) pyruvate to total carbon ratio of HCC tumors (black pluses) (more ...)
We report a technique to measure localized T2 relaxation times of 13C-labeled metabolites in vivo, and the comparison between an HCC rat model and normal rat liver. To the best of our knowledge, this is the first report on in vivo localized T2 measurements of 13C metabolites. The large signal enhancement afforded by the hyperpolarized 13C MRS technique made such measurements possible in vivo. Atomic motion influences the rate of transverse relaxation, and such motion varies in different microscopic environment depending on viscosity, temperature, local magnetic fields, and surrounding molecules. Therefore, the T2 measured in vivo may be particularly relevant to the design of imaging sequences and contrast generation strategies for in vivo hyperpolarized 13C applications. The 13C-alanine and 13C-lactate T2 relaxation times were found to be about half a second in the normal liver. For comparisons, the relaxation time for 13C-lactate due to spin-spin coupling (JCH) was about 25 ms (41) and a similar JCH coupling for 13C-alanine. Imaging sequences acquiring T2 signal may have advantages in SNR and/or large matrix size. The large difference in T2 relaxation time between HCC tumor and normal liver could provide an opportunity to develop novel strategies for enhancing image contrast and improving cancer detection.
One of the limitations with the in vivo measurement presented here was that metabolic conversions continued during data acquisition. Typical conversion rates from pyruvate to lactate or pyruvate to alanine range from 0.004 to 0.07 s−1 (11,34), corresponding to time constants longer than 14 s. Hence, during the 8-s T2 acquisition time, a very small number of 13C labels may have exchanged from one metabolite to another.
Another limitation of this technique is the possible variations in voxel placement due to respiratory motion. Although no appreciable liver displacement relative to the voxel was observed in repeated T2W proton images, contribution of extrahepatic tissues such as fat during respiration was almost unavoidable when measuring T2 in vivo. Extend of this variability contributed to the intra and inter subject variations reported in this work. The partial volume effect due to respiratory motion may also affect tumor T2 measurements, resulting an underestimate of T2 if non-cancerous liver tissue contributed to the measured signal, or overestimate of T2 if vasculature contributed to the measured signal. Given the highly heterogeneous nature of this tumor model as examined by necropsies and the limited spatial resolution of this approach, further uncertainty was added to this circumstance. Gd enhanced images (or SPIO images) of the same hepatic tumors, after 13C MRS, would have provided a more clear picture of tumor heterogeneity and partial volume effects, helping a better interpretation of the results. For future studies, respiratory gating can be used to improve the consistency of voxel placements between proton scout scans and 13C acquisitions.
We found that T2 of 13C-alanine and 13C-lactate in rat HCC tumors were longer than those in the normal liver tissue. This may be related to tumor cell morphology and leaky vessels in the fast growing tumors. The improved localization of T2 in this voxel-based study eliminated some of the complexity in the previous whole-slice study (13). Most notably, a very long T2 component (2–3 s) previously observed in the whole-slice study was not observed in this study even when we tried bi- or tri-exponential fittings (results not shown here). This may not be surprising since significant signal from the intravascular space was included in the whole-slice data, and the proper noise correction (39) was not applied in the data analysis of the whole-slice study. The sensitivity of this technique to very short T2 components (100 to 250 ms as previously reported (13)) was somewhat limited by the delayed acquisition (78 ms) due to the voxel selection pulses.
Besides variations in T2 relaxation, injection dose and T1 relaxation from dissolution to injection, which were corrected in the data analysis, the total carbon signal could also be affected by the DNP solid-state build-up of the 13C-pyruvate sample, variations in the liquid state polarization due to the dissolution process, and/or the voxel position and heterogeneity of the liver. Despite these variations, there is a trend towards higher total carbon signal in HCC tumors than that in normal livers. Since all detectable 13C signal came from the injected 13C-pyruvate, the high total carbon signal found in tumors may be due to the high metabolism expected in tumor cells or the high perfusion in these highly vascular tumors, or both. Techniques capable of differentiating signals from within cells versus signals in blood (42) will be very important for more detailed characterization of cancerous tumors using hyperpolarized 13C-MRS.
The ratio of individual metabolite signals to the total carbon signal is, however, independent of many of the variations in experimental conditions mentioned above; and therefore, the ratio is a good ‘first-order’ indicator of enzymatic activity. We found the alanine to total carbon ratio is significantly higher in HCC tumors than in normal livers. This may be related to the reported high ALT level in the Morris HCC rat model (35,36). Even though the same amount of hyperpolarized 13C-pyruvate solution was injected in each animal, the up-take of 13C-pyruvate by each HCC tumor varies, as indicated by the wide range of total carbon signal found in HCC tumors (Fig. 5). The up-take of 13C-pyruvate may depend on the tumor vasculature, monocarboxylate transporters, and metabolic activity. But the almost linear relationship between the total carbon and the labeled alanine signals observed in HCC tumors (red stars in Fig. 5) is very interesting. This may imply that the enzymatic activity in the HCC tumor cell is so high that it stays ‘unsaturated’ even with the high doses of 13C-pyruvate injected in this study. An alternative interpretation as proposed by Day et al. (11) is that the observed differences in alanine to total carbon ratios between HCC tumor and normal liver result from passive exchange with a pre-existing alanine pool. Based on this interpretation, our data showing higher alanine than lactate production in the Morris 7777 tumors may imply there is more alanine than lactate in this tumor model. Unfortunately, we are not able to find alanine and lactate concentrations measured in Morris 7777 tumors in literature. This may be of future interest but is outside of the scope of this work.
This study showed similar lactate to total carbon ratios between HCC tumors and normal livers (Fig. 6b); very different from the elevated lactate to total carbon ratios previously reported by other tumor studies (2,6,810). This may also be due to the particular animal model used here. Studies done by Weber et al. (29,35) and Shonk et al. (30) on metabolism regulations in Morris HCC models found that in spite of correlation between the increasing growth rate and increased lactate production, the LDH level in the fast growing HCC model [approximately 135 μmole/min/g w-w in average (30)] is not higher than the LDH level in the normal liver [162 μmole/min/g w-w (30)]. In another study comparing a fast-growing HCC model to a slow-growing one, Fields et al. (31) found that the fast-growing model (Morris hepatoma 7777, in particular) is not able to oxidize fat. Therefore, it must derive all of its calories from protein or carbohydrate sources. We postulate that the Morris hepatoma 7777 model may have elevated lactate production due to high consumption of pyruvate as a fuel but the pyruvate to lactate conversion rate may be similar to normal liver, as indicated to the first-order by the similar lactate to total carbon ratios found here (Fig. 6b) in the presence of a pyruvate concentration higher than the normal physiological level. A better experiment to evaluate the pyruvate to lactate conversion in vivo using hyperpolarized 13C technique would be to perform a localized dynamic acquisition from the start of hyperpolarized 13C-pyruvate injection and to extract the apparent Vmax (the maximum reaction rate) from the Michaelis-Menten kinetics (43). Such an experiment is beyond the scope of this study but will be of future interest.
It is important to note that in addition to the LDH activity, the labeled lactate signal to the total carbon ratio also depends on in flow and transport. The monocarboxylate transporters will equilibrate pyruvate and lactate, as determined by the intra- and extracellular pH gradient, exchanging these metabolites much faster between the intracellular and extracellular spaces than LDH activity. This exchange between different vascular, extracellular and intracellular environments in control and HCC may be an additional source of the wide range of total carbon and lactate signals found in HCC tumors.
The similar ratio of labeled lactate to total carbon discovered here was after injections of unphysiologically high concentration of pyruvate. Under physiological conditions, LDH is not a rate-limiting enzyme of glycolysis. The glycolytic flux and lactate production are determined upstream in the glycolytic pathway at the hexokinase, phosphofructokinase and pyruvate kinase steps. Thus the finding of similar ratio of 13C labeled lactate to the total 13C in normal liver and HCC tumor does not imply that the HCC tumor will not produce more lactate from glucose than the normal liver under physiological conditions since all the rate limiting steps prior to LDH in tumor may be different or altered.
A single-voxel CPMG sequence was developed to measure both signal intensities and T2 relaxation times of 13C-labeled metabolites in vivo following hyperpolarized 13C-pyruvate injections in rats with hepatocellular carcinomas and healthy control rats. The 13C-alanine T2 was 1.2 ± 0.1 s in HCC tumor and 0.38 ± 0.05 s in normal liver. The 13C-lactate T2 was 0.9 ± 0.2 s in HCC tumor and 0.52 ± 0.03 s in normal liver. The T2 of alanine and lactate were both significantly longer in HCC tumors than in normal livers. The alanine to total carbon ratio in HCC tumors was also significantly higher (1.5 ± 0.5 times) than that in normal livers, but the lactate to total carbon ratio was comparable between the tumors and normal livers. The intra- and inter-subject variabilities were 11% and 13%, respectively, for alanine T2 estimates and 6% and 7%, respectively, for lactate T2 estimates. The intra-subject variability of alanine to total carbon ratio was 16% and the inter-subject variability 28%. The intra-subject variability of lactate to total carbon ratio was 14% and the inter-subject variability 20%. We conclude that 13C-alanine may be a promising biomarker for hepatocellular carcinoma tumors, but its full diagnostic value in hepatocellular carcinoma staging and treatment monitoring is yet to be explored. The quantitative T2 relaxation times reported here are important parameters for pulse sequence designs and a potential source of image contrast in hyperpolarized 13C metabolic imaging applications.
Acknowledgments
Contract/grant sponsor: National Institutes of Health P41-RR09784, P50-CA114747, R01-AA005965, R01-CA121163, U01-AA013521 (INIA), R01-EB009070.
We appreciate help from Dr Young Il Kim and Ms Regina Katzenberg for the HCC model preparation. We thank Mr Oliver Hsu and Mr Evan Nunez for their diligent work on animal handling during the hyperpolarized 13C experiments. We also express our gratitude to Dr Moses Darpolor for valuable discussions on metabolic regulation in Morris HCC models. Support of this work was provided by grants P41-RR09784, P50-CA114747, R01-AA005965, R01-CA121163, U01-AA013521 (INIA), R01-EB009070.
Abbreviations used
ALTAlanine transaminase
APLACAdministrative Panel on Laboratory Animal Care
CPMGCarr–Purcell–Meiboom–Gill
CTComputed tomography
EDTAEthylene diamine tetraacetic acid
GEGeneral Electric
HCCHepatocellular carcinoma
LASERLocalization by Adiabatic Selective Refocusing
LDHLactate dehydrogenase
MRIMagnetic resonance imaging
MRSMagnetic resonance spectroscopy
RFRadio frequency
SLRShinnar–Le Roux
SNRSignal to noise ratio
stdStandard deviation
T2WT2 weighted
TRAMPTransgenic adenocarcinoma of mouse prostate
TRIStrishydroxymethylaminomethane

1. Schroeder MA, Atherton HJ, Ball DR, Cole MA, Heather LC, Griffin JL, Clarke K, Radda GK, Tyler DJ. Real-time assessment of Krebs cycle metabolism using hyperpolarized 13C magnetic resonance spectroscopy. FASEB J. 2009 Mar 27; Epub. [PubMed]
2. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68(20):8607–8615. [PMC free article] [PubMed]
3. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med. 2008;60:253–257. [PubMed]
4. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature. 2008;453(7197):940–943. [PubMed]
5. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Månsson S. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. Magn Reson Med. 2008;59:1005–1013. [PubMed]
6. Kurhanewicz J, Bok R, Nelson SJ, Vigneron DB. Current and potential applications of clinical 13C MR spectroscopy. J Nucl Med. 2008;49:341–344. [PMC free article] [PubMed]
7. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci USA. 2007;104(50):19773–19777. [PubMed]
8. Chen AP, Bok R, Zhang V, Xu D, Veeraraghavan S, Hurd RE, Nelson SJ, Kurhanewicz J, Vigneron DB. Serial hyperpolarized 13C 3D-MRSI following therapy in a mouse model of prostate cancer. Proceedings of the 16th Annual Meeting of ISMRM; Toronto, Canada. 2008; p. 888.
9. Chen AP, Albers MJ, Cunningham CH, Kohler SJ, Yen YF, Hurd RE, Tropp J, Bok R, Pauly JM, Nelson SJ, Kurhanewicz J, Vigneron DB. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-Initial experience. Magn Reson Med. 2007;58(6):1099–1106. [PubMed]
10. Golman K, in't Zandt R, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006;66(22):10855–10860. [PubMed]
11. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nature Med. 2007;13(11):1382–1387. [PubMed]
12. Golman K, Olsson LE, Axelsson O, Månsson S, Karlsson M, Petersson JS. Molecular imaging using hyperpolarized13C. Br J Radiol. 2003;76(Spec No 2):S118–127. [PubMed]
13. Yen YF, Le Roux P, Bok R, Tropp J, Chen AP, Zhang VY, Zierhut ML, Albers MJ, Park I, Nelson SJ, Vigneron DB, Kurhanewicz J, Hurd RE. Apparent T2 of 13C-labeled metabolites in vivo. Proceedings of the 16th Annual Meeting of ISMRM; Toronto, Canada. 2008; p. 1747.
14. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J Magn Reson. 2001;153:155–177. [PubMed]
15. Silver MS, Joseph RI, Hoult DI. Highly selective ¼ = 2 and ¼ pulse generation. J Magn Reson. 1984;59:347–351.
16. Baum J, Tycko R, Pines A. Broadband and adiabatic inversion of a two-level system by phase-modulated pulses. Phys Rev. 1985;A 32:3435–3447. [PubMed]
17. Hardy CJ, Edelstein WA, Vatis D. Efficient adiabatic fast passage for NMR population inversion in the presence of radiofrequency field inhomogeneity and frequency offsets. J Magn Reson. 1986;66:470–482.
18. Ugurbil K, Garwood M, Rath A. Optimization of modulation functions to improve insensitivity of adiabatic pulses to variations in B1magnitude. J Magn Reson. 1988;80:448–469.
19. Tannus A, Garwood M. Adiabatic pulses. NMR Biomed. 1997;10:423–434. [PubMed]
20. Pauly J, Le Roux P, Nishimura D, Macovski A. Parameter relations for the Shinnar-Le Roux selective excitation pulse design algorithm. IEEE Trans Med Imag. 1991;10:53–65. [PubMed]
21. Le Roux P, Gilles R, McKinnon G, Carlier P. Optimized outer volume suppression for single-shot fast spin-echo cardiac imaging. J Magn Reson Imag. 1998;8:1022–1032. [PubMed]
22. Schulte RF, Taso J, Boesiger P, Pruessman KP. Equi-ripple design of quadratic-phase RF pulses. J Magn Reson. 2004;166:111–122. [PubMed]
23. Ravoet C, Bleiberg H, Gerard B. Non-surgical treatment of hepatocellubar carcinoma. J Surg Oncol. 1993;3(Suppl):104–ill. [PubMed]
24. Venook AP. Treatments of hepatocellular carcinoma: too many options? J Clin Oncol. 1994;12:1323–1334. [PubMed]
25. Holland AE, Hecht EM, Hahn WY, Kim DC, Babb JS, Lee VS, West AB, Krinsky GA. Importance of Small (≤20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology. 2005;237:938–944. [PubMed]
26. Morris HP. Progress in Experimental Tumor Research. Vol. 3. Karger; 1963. Some growth, morphological, and biochemical characteristics of hepatoma 5123 and other new transplantable hepatomas; pp. 370–411. [PubMed]
27. Weber G. Introductory remarks on some basic concepts in neoplasia. Cancer Res. 1963;23:1471–1473. [PubMed]
28. Elwood JC, Lin YC, Cristofalo VJ, Weinhouse S, Morris HP. Glucose utilization in homogenates of the Morris hepatoma 5123 and related tumors. Cancer Res. 1963;23:906–913. [PubMed]
29. Weber G, Henry MC, Wagle SR, Wagle DS. Correlation of enzyme activities and metabolic pathways with growth rate of hepatomas. Adv Enzyme Regul. 1964;2:335–346. [PubMed]
30. Shonk CE, Morris HP, Boxer GE. Patterns of glycolytic enzymes in rat liver and hepatoma. Cancer Res. 1965;25:671–676. [PubMed]
31. Fields ALA, Wolman SL, Cheema-Dhadli S, Morris HP, Halperin ML. Regulation of Energy Metabolism in Morris Hepatoma 7777 and 78001. Cancer Res. 1981;41:2762–2766. [PubMed]
32. Morris HP, Wagner BP. Proceedings of the 8th International Congress on Cancer; Moscow, Russia. 1962, 1964.1965. Acta Union Int Contro Cancer 1962, 1964. 20:1364–1366.
33. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. [PubMed]
34. Zierhut ML, Chen AP, Bok R, Albers MJ, Zhang V, Pels P, Tropp J, Park I, Vigneron DB, Kurhanewicz J, Hurd RE, Nelson SJ, Yen YF. Kinetic modeling of hyperpolarized 13c1-pyruvate metabolism using dynamic magnetic resonance spectroscopy. Proceedings of the 15th Annual Meeting of ISMRM; Berlin, Germany. 2007; p. 366.
35. Weber G, Morris HP. Comparative biochemistry of hepatomas III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res. 1963;23:987–994. [PubMed]
36. Pfab T, Stoltenburg-Didinger G, Trautner C, Godes M, Bauer C, Hocher B. The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo. Br J Pharmacol. 2004;141:215–222. [PubMed]
37. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100:10158–10163. [PubMed]
38. Derby K, Tropp J, Hawryszko C. Design and evaluation of a novel dual-tuned resonator for spectroscopic imaging. J Magn Reson. 1990;86(3):645–651.
39. Henkelman RM. Measurement of signal intensities in the presence of noise in MR images. Med Phys. 1985;12(2):232–233. [PubMed]
40. Hu S, Chen AP, Zierhut ML, Bok R, Yen YF, Schroeder M, Hurd RE, Nelson SJ, Kurhanewicz J, Vigneron DB. In vivo carbon-13 dynamic MRS and MRSI of normal and fasted rat liver with hyperpolarized 13C-pyruvate. Molec Imag Biol. 2009 in press. [PMC free article] [PubMed]
41. Kohler SJ, Yen Y, Wolber J, Chen AP, Albers MJ, Bok R, Zhang V, Tropp J, Nelson SJ, Vigneron DB, Kurhanewicz J, Hurd RE. In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med. 2007;58(1):65–69. [PubMed]
42. Peterson ET, Gordon JW, Kurpad KN, Fain SB, Rowland IJ. Probing the in vivo compartmentalization of hyperpolarized pyruvate using gadodiamide-induced T1 relaxation. Proceedings of the 17th Annual Meeting of ISMRM; Honolulu, USA. 2009; p. 2417.
43. Michaelis L, Menten M. Die Kinetik der Invertinwirkung. Biochem Z. 1913;49:333–369.